SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending amid speculation and excitement surrounding potential deals with major players like Google in the AI and data center space, following news of a $3 billion agreement with Fluidstack. Community members are actively debating the impact of a recent convertible note offering and the company's strategic shift towards AI infrastructure. Bullish sentiment revolves around the expectation of more deals and significant revenue growth, while bears express concerns about dilution and market manipulation.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as traders discuss the newly available options chain and the stock's recent volatility. Community members are debating whether the company's valuation is justified given its lack of revenue, drawing comparisons to other hyped stocks and potential market manipulation. Bearish sentiment appears to be increasing as some anticipate a significant correction, while others remain bullish on the company's long-term potential in the nuclear energy sector.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors discuss the potential approval pathway for its Duchenne Muscular Dystrophy (DMD) treatment, Deramiocel, following regulatory updates and a Type A meeting with the FDA. The community is focused on the possibility of submitting HOPE-3 trial data within the current Biologics License Application (BLA), with some expressing concerns about the primary endpoint and others highlighting potential for a short squeeze given high short interest.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending downwards, prompting discussions about whether this marks the start of a significant correction. Community members are debating the impact of economic data and potential Fed actions on the ETF's direction, with some anticipating a deeper pullback while others foresee a quick recovery.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to an expanded agreement with OpenAI valued at up to $6.5 billion, bringing the total contract value to $22.4 billion, which investors see as a major catalyst. Despite market volatility, the community is optimistic about CoreWeave's strong position in the AI infrastructure space and its partnership with Nvidia. Some traders are also closely watching upcoming events, like the Jefferies Virtual AI Summit, for further developments.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market experiences volatility, sparking debates about potential bottom levels and future price movements. Community members are actively discussing market manipulation, the influence of external factors like government shutdowns, and the impact of large players like Binance and Tom Lee. Despite the uncertainty, some investors see the dip as a buying opportunity, while others express concerns about long-term prospects.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF ($IWM) is trending as it approaches all-time highs, driven by optimism surrounding potential rate cuts and a rotation into small-cap stocks. Community discussions revolve around whether this rally is sustainable or if a pullback is imminent, with some traders pointing to technical indicators suggesting overbought conditions and others highlighting the potential for further gains. Overall, traders are watching closely to see if $IWM can break through resistance and continue its upward trajectory.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amidst discussions around its valuation and recent quantum computing advancements, specifically a breakthrough in converting photons to telecom wavelengths. While some traders are bullish, citing potential government contracts and a possible short squeeze, others express concern over the stock's high valuation and cash burn rate, pointing to insider selling and the possibility of a market correction. Community members are actively debating the company's long-term potential and whether current prices are sustainable.

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

PepGen Inc

PepGen Inc is trending as discussions revolve around its recent public offering and the implications for the stock's future. While some community members express concerns about potential dilution and a possible reverse split, others highlight the company's clinical trial results and potential for significant gains. The stock's volatile price movement and potential short squeeze are also being actively discussed.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders weigh recent market pullbacks against potential upside catalysts. Community discussions focus on whether current dips represent buying opportunities or the start of a larger correction, with some pointing to specific levels to watch. Economic data releases and overall market sentiment are also key factors influencing the conversation around QQQ.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock.Hunterbrook <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom/">said</a> on Thursday that it has a short position on DXCM based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s flagship G7 continuous glucose monitor (CGM) device, “some diabetics are ending up in the ICU — or dead.” Hunterbrook Media is an investigative news outlet.The report stated that DexCom made an unauthorized design change to a key component of the G7 that internal studies showed was inferior by “every accuracy metric,” and the company sold the device anyway. This change was revealed during a surprise inspection by the U.S. Food and Drug Administration (FDA), the report stated.Several company executives left the company amid the FDA’s scrutiny and soaring complaints, the report said, while adding that patients are now returning to the G6 or switching to products from competitors, such as Abbott (ABT).Hunterbrook also stated that it has shared its probe with a senior official from the Health and Human Services (HHS) and requested that the FDA intervene. The firm also said that DexCom didn't respond to their requests for comments. The report named people who died or had to be hospitalized following wrong readings by the G7 device, including Billy Sosbe, who died in June, and Diana Bates Knight, who rushed her 6-year-old to the emergency, after the device misread her blood sugar by hundreds of points.“In Dexcom’s crisis, Abbott may see its chance. Our analysis of FDA data shows Dexcom receives more accuracy complaints than its market share predicts; Abbott receives significantly fewer,” Hunterbrook said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DXCM">DXCM</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_2_14_55_PM_png_eb2477f011.webp" alt="DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that DexCom has proven technology and is leading in CGM.<stembedurl>https://stocktwits.com/CmonManGiveMeABreak/message/629329227</stembedurl>Another user, however, opined that the FDA might pull the G7 device from the market.<stembedurl>https://stocktwits.com/buddyopalosam/message/629325830</stembedurl>DXCM stock is down by 13% this year and by 5% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/kalvista-pharmaceuticals-hereditary-angioedema-drug-approved-in-eu-switzerland/chD3BkIR3TW">KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the DexCom logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that some diabetics died after inaccurate readings from Dexcom’s G7  device.

Equity

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s G7 continuous glucose monitor device, some diabetics are ending up in the ICU or dead.


Investing in the Age of Longevity: Silver Economy Stocks in Focus

AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.

Why Is DexCom (DXCM) Down 7% Since Last Earnings Report?

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Dexcom Announces Upcoming Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on...

DexCom Expands Access and Innovation While Balancing Headwinds

DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?

ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.

DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise

DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.

Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

DexCom (DXCM) Q2 Earnings and Revenues Top Estimates

DexCom (DXCM) delivered earnings and revenue surprises of +6.67% and +3.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

Costco Wholesale Corp

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

DXCM
Dexcom Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DXCM News

DXCM Dexcom Inc